300006.SZ SHZ
Chongqing Lummy Pharmaceutical Co., Ltd.
1W: +0.0%
1M: -2.6%
3M: +11.9%
YTD: +8.2%
1Y: +9.0%
3Y: +62.1%
5Y: -23.0%
¥5.56 ($0.83)
+0.26 (+4.91%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Balance Sheet Trends
Total Assets
$2.6B
-9.8% ▼
5Y CAGR: -3.9%
Total Liabilities
$806M
-17.1% ▼
5Y CAGR: -15.9%
Shareholders Equity
$1.8B
-6.4% ▼
5Y CAGR: +8.4%
Cash & Investments
$926M
-13.6% ▼
5Y CAGR: +11.2%
Total Debt
$379M
-2.4% ▼
5Y CAGR: -20.0%
Net Debt
-$503M
+26.5% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $559M | $846M | $836M | $1.1B | $881M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $45M |
| Cash & ST Investments | $559M | $846M | $836M | $1.1B | $926M |
| Net Receivables | $985M | $348M | $608M | $453M | $402M |
| Inventory | $158M | $202M | $171M | $202M | $161M |
| Other Current Assets | $564M | $348M | $4M | $11M | $0 |
| Total Current Assets | $1.7B | $1.7B | $1.6B | $1.8B | $1.5B |
| Property, Plant & Equip. | $394M | $340M | $287M | $275M | $282M |
| Goodwill & Intangibles | $208M | $273M | $245M | $262M | $227M |
| Long-Term Investments | $487M | $531M | $516M | $0 | $387M |
| Other Non-Current Assets | $6M | $49M | $65M | $420M | $4M |
| Total Non-Current Assets | $1.2B | $1.3B | $1.2B | $1.1B | $1.1B |
| Total Assets | $2.9B | $3.1B | $2.9B | $2.9B | $2.6B |
| — Liabilities — | |||||
| Accounts Payable | $34M | $50M | $38M | $66M | $93M |
| Short-Term Debt | $130M | $122M | $114M | $243M | $320M |
| Deferred Revenue | $445M | $439M | $0 | $0 | $13M |
| Other Current Liabilities | $482M | $498M | $412M | $122M | $248M |
| Total Current Liabilities | $667M | $701M | $562M | $802M | $728M |
| Long-Term Debt | $0 | $149M | $126M | $141M | $57M |
| Other Non-Current Liab. | $25M | $0 | $58M | $0 | $0 |
| Total Non-Current Liabilities | $48M | $169M | $206M | $171M | $78M |
| Total Liabilities | $715M | $870M | $769M | $972M | $806M |
| — Equity — | |||||
| Common Stock | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Retained Earnings | -$413M | -$460M | -$469M | -$555M | -$805M |
| Accumulated OCI | $54M | $54M | $0 | $0 | -$2M |
| Total Stockholders Equity | $2.2B | $2.1B | $2.1B | $1.9B | $1.8B |
| Total Liabilities & Equity | $2.9B | $3.1B | $2.9B | $2.9B | $2.6B |
| — Key Metrics — | |||||
| Total Debt | $195M | $365M | $243M | $388M | $379M |
| Net Debt | -$365M | -$481M | -$562M | -$684M | -$503M |
| Total Investments | $487M | $531M | $516M | $0 | $432M |